H1-antihistamines are recognized to be effective for conditions such as allergic rhinitis and chronic spontaneous urticaria. However, management of such conditions in the real-world primary care setting may be challenging due to diverse patient-specific considerations, the wide range of antihistamines available, choice of other treatment modalities, and the complexity of interpreting specialist treatment algorithms. Despite regular updates to international guidelines, regional/national surveys of healthcare professionals show a clear gap between guidelines and real-world practice, particularly at the primary care level. This article thus presents the consensus opinion of experts from relevant specialties in Malaysia – allergology, pediatrics, otorhinolaryngology, and dermtology – on harmonizing the use and choice of antihistamines in primary care. Patient profiling is recommended as a tool to guide primary care practitioners in prescribing the appropriate antihistamine for each patient. Patient profiling is a three-step approach that involves 1) identifying the individual’s needs; 2) reviewing patient-specific considerations; and 3) monitoring treatment response and referral to specialists in more severe or difficult-to-treat cases. Concurrently, guidelct 3ines should be reviewed and updated periodically to include recommendations that are easily actionable for primary care practitioners.

1. Koberlein, J., Vent, J., & Mösges, R. (2010). On the sustainability of guideline implementation. World Allergy Organization Journal, 3, 258–261. https://doi.org/10.1097/WOX.0b013e3181fdfc7a
2. Kulthanan, K., Chusakul, S., Recto, M. T., et al. (2018). Economic burden of the inadequate management of allergic rhinitis and urticaria in Asian countries based on the GA(2)LEN model. Allergy Asthma & Immunology Research, 10(4), 370–378. https://doi.org/10.4168/aair.2018.10.4.370
3. Simons, F. E. R., & Simons, K. J. (2011). Histamine and H1-antihistamines: Celebrating a century of progress. Journal of Allergy and Clinical Immunology, 128(6), 1139–1150.e4. https://doi.org/10.1016/j.jaci.2011.09.005
4. Dávila, I., Del Cuvillo, A., Mullol, J., et al. (2013). Use of second-generation H1 antihistamines in special situations. Journal of Investigational Allergology and Clinical Immunology, 23(Suppl 1), 1–16.
5. Prepageran, N., Wang, D. Y., Nair, G., & Maurer, M. (2014). The status quo and unmet needs in the management of allergic rhinitis and chronic rhinosinusitis: A Malaysian perspective. Asia Pacific Allergy, 4(3), 142–148. https://doi.org/10.5415/apallergy.2014.4.3.142
6. Fitzsimons, R., van der Poel, L. A., Thornhill, W., et al. (2015). Antihistamine use in children. Archives of Disease in Childhood: Education and Practice Edition, 100(3), 122–131. https://doi.org/10.1136/archdischild-2013-304446
7. Kar, S., Krishnan, A., Preetha, K., & Mohankar, A. (2012). A review of antihistamines used during pregnancy. Journal of Pharmacology & Pharmacotherapeutics, 3(2), 105–108. https://doi.org/10.4103/0976-500X.95503
8. Kay, G. G., & Quig, M. E. (2001). Impact of sedating antihistamines on safety and productivity. Allergy Asthma Proceedings, 22(5), 281–283.
9. Kuna, P., Jurkiewicz, D., Czarnecka-Operacz, M. M., et al. (2016). The role and choice criteria of antihistamines in allergy management – Expert opinion. Postępy Dermatologii i Alergologii, 33(5), 397–410. https://doi.org/10.5114/pdia.2016.63942
10. McCue, J. D. (1996). Safety of antihistamines in the treatment of allergic rhinitis in elderly patients. Archives of Family Medicine, 5(8), 464–468.
11. Yang, H. J., Kim, Y. H., Lee, B., et al. (2017). Unmet primary physicians’ needs for allergic rhinitis care in Korea. Allergy Asthma & Immunology Research, 9(3), 265–271. https://doi.org/10.4168/aair.2017.9.3.265
12. Scadding, G. K., & Williams, A. (2008). The burden of allergic rhinitis as reported by UK patients compared with their doctors. Rhinology, 46(2), 99–106.
13. Recto, M. T., Gabriel, M. T., Kulthanan, K., et al. (2017). Selecting optimal second-generation antihistamines for allergic rhinitis and urticaria in Asia. Clinical and Molecular Allergy, 15, 19. https://doi.org/10.1186/s12948-017-0074-3
14. Bousquet, J., Khaltaev, N., Cruz, A. A., et al. (2008). Allergic rhinitis and its impact on asthma (ARIA) 2008 update. Allergy, 63(Suppl 86), 8–160. https://doi.org/10.1111/j.1398-9995.2007.01620.x
15. Zuberbier, T., Aberer, W., Asero, R., et al. (2018). The EAACI/GA2LEN/EDF/WAO guideline for urticaria. Allergy, 73(7), 1393–1414. https://doi.org/10.1111/all.13397
16. Del Cuvillo, A., Sastre, J., Montoro, J., et al. (2007). Use of antihistamines in pediatrics. Journal of Investigational Allergology and Clinical Immunology, 17(Suppl 2), 28–40.
17. Bayer Healthcare. (2015). Clarityne® tablet & syrup.
18. GlaxoSmithKline Pharmaceutical Sdn Bhd. (2018). Zyrtec film-coated tablet/oral solution/oral drops (cetirizine dihydrochloride).
19. HOE Pharmaceuticals Sdn. Bhd. (2014). Zoralix 5 SF elixir 5 mg/5 mL.
20. Kotra Pharma (M) Sdn. Bhd. (n.d.). Axcel® chlorpheniramine syrup.
21. Merck Sharp & Dohme (Malaysia) Sdn. Bhd. (2018). Aerius® syrup (desloratadine 0.5 mg/mL).
22. Sanofi-aventis (Malaysia) Sdn. Bhd. (2017). Telfast® oral suspension (fexofenadine hydrochloride 30 mg/5 mL).
23. Sunward Pharmaceutical Sdn. Bhd. (2019). Polarax tablet/syrup.
24. Upha Pharmaceutical Mfg. (M) Sdn. Bhd. (2016). Chloramine syrup.
25. Xepa-Soul Pattinson (Malaysia) Sdn Bhd. (2017). Antamin™ syrup.
26. Chainani, E., Godse, K., Agarwal, S., & Patil, S. (2015). Knowledge and attitude of medical resident doctors toward antihistamines. Indian Journal of Dermatology, 60(6), 635. https://doi.org/10.4103/0019-5154.169141
27. Simons, F. E. R., & Simons, K. J. (2008). H1 antihistamines: Current status and future directions. World Allergy Organization Journal, 1, 145–155. https://doi.org/10.1186/s40413-018-0188-1
28. Randall, K. L., & Hawkins, C. A. (2018). Antihistamines and allergy. Australian Prescriber, 41(2), 41–45. https://doi.org/10.18773/austprescr.2018.013
29. Vuurman, E. F., van Veggel, L. M., Uiterwijk, M. M., Leutner, D., & O’Hanlon, J. F. (1993). Seasonal allergic rhinitis and antihistamine effects on children’s learning. Annals of Allergy, 71, 121–126.
30. Blaiss, M. S., & Allergic Rhinitis in Schoolchildren Consensus Group. (2004). Allergic rhinitis and impairment issues in schoolchildren. Current Medical Research and Opinion, 20(12), 1937–1952. https://doi.org/10.1185/030079904x13266
31. Kay, G. G. (2000). The effects of antihistamines on cognition and performance. Journal of Allergy and Clinical Immunology, 105(6), S622–S627. https://doi.org/10.1067/mai.2000.106153
32. Church, M. K., Maurer, M., Simons, F. E. R., et al. (2010). Risk of first-generation H1-antihistamines. Allergy, 65(4), 459–466. https://doi.org/10.1111/j.1398-9995.2009.02325.x
33. Yang, Y. H., Lin, Y. T., Lu, M. Y., Tsai, M. J., & Chiang, B. L. (2001). Loratadine syrup in children with allergic rhinitis. Asia Pacific Journal of Allergy and Immunology, 19, 171–175.
34. Garavello, W., Romagnoli, M., Sordo, L., et al. (2003). Hypersaline nasal irrigation in children with seasonal allergic rhinitis. Pediatric Allergy and Immunology, 14(2), 140–143.
35. Batchelor, H. K., & Marriott, J. F. (2015). Formulations for children: Problems and solutions. British Journal of Clinical Pharmacology, 79(3), 405–418. https://doi.org/10.1111/bcp.12268
36. Nunn, T., & Williams, J. (2005). Formulation of medicines for children. British Journal of Clinical Pharmacology, 59(6), 674–676. https://doi.org/10.1111/j.1365-2125.2005.02410.x
37. Banfield, C., Gupta, S., Marino, M., et al. (2002). Grapefruit juice reduces oral bioavailability of fexofenadine. Clinical Pharmacokinetics, 41(4), 311–318. https://doi.org/10.2165/00003088-200241040-00004
38. Sadaba, B., Azanza, J. R., Gomez-Guiu, A., & Rodil, R. (2013). Critical appraisal of bilastine. Therapeutics and Clinical Risk Management, 9, 197–205. https://doi.org/10.2147/TCRM.S16079
39. Bailey, D. G. (2010). Fruit juice inhibition of uptake transport. British Journal of Clinical Pharmacology, 70(6), 645–655. https://doi.org/10.1111/j.1365-2125.2010.03722.x
40. Meltzer, E. O., Blaiss, M. S., Naclerio, R. M., et al. (2012). Burden of allergic rhinitis. Allergy Asthma Proceedings, 33(Suppl 1), S113–S141. https://doi.org/10.2500/aap.2012.33.3603
41. Yun, J., Katelaris, C. H., Weerasinghe, A., et al. (2011). Impact of chronic urticaria on quality of life. Asia Pacific Allergy, 1(1), 25–29. https://doi.org/10.5415/apallergy.2011.1.1.25
42. Kay, G. G., Berman, B., Mockoviak, S. H., et al. (1997). Effects of diphenhydramine and loratadine on performance. Archives of Internal Medicine, 157(21), 2350–2356.
43. Wilken, J. A., Berkowitz, R., & Kane, R. (2002). Cognitive impairment in allergic rhinitis. Annals of Allergy, Asthma & Immunology, 89(4), 372–380. https://doi.org/10.1016/S1081-1206(10)62038-8
44. Simons, F. E. R., Fraser, T. G., Reggin, J. D., & Simons, K. J. (1996). CNS effects of H1 antihistamines. Clinical and Experimental Allergy, 26(10), 1092–1097.
45. Federal Aviation Administration. (2019). Guide for aviation medical examiners: Pharmaceuticals (therapeutic medications). https://www.faa.gov/
46. Staevska, M., Gugutkova, M., Lazarova, C., et al. (2014). Night-time sedating antihistamines in urticaria. British Journal of Dermatology, 171(1), 148–154. https://doi.org/10.1111/bjd.12846
47. Herman, D., Arnaud, A., Dry, J., et al. (1992). Loratadine vs cetirizine. Allergie et Immunologie (Paris), 24, 270–274.
48. Mann, R. D., Pearce, G. L., Dunn, N., & Shakir, S. (2000). Sedation with non-sedating antihistamines. BMJ, 320, 1184–1186. https://doi.org/10.1136/bmj.320.7243.1184
49. Salmun, L. M., Gates, D., Scharf, M., et al. (2000). Loratadine vs cetirizine somnolence study. Clinical Therapeutics, 22(5), 573–582. https://doi.org/10.1016/S0149-2918(00)80045-4
50. Ramaekers, J. G., Uiterwijk, M. M., & O’Hanlon, J. F. (1992). Effects of loratadine and cetirizine on driving. European Journal of Clinical Pharmacology, 42, 363–369. https://doi.org/10.1007/BF00280119
51. Georgitis, J. W., Meltzer, E. O., Kaliner, M., et al. (2000). Antihistamine and decongestant onset of action. Annals of Allergy, Asthma & Immunology, 84(4), 451–459. https://doi.org/10.1016/S1081-1206(10)62280-6
52. Kaiser, H. B., Banov, C. H., Berkowitz, R. R., et al. (1998). Loratadine-pseudoephedrine combinations. American Journal of Therapeutics, 5(4), 245–251.
53. Lockey, R. F. (2006). Rhinitis medicamentosa. Journal of Allergy and Clinical Immunology, 118(5), 1017–1018. https://doi.org/10.1016/j.jaci.2006.06.018
54. Mortuaire, G., de Gabory, L., François, M., et al. (2013). Rhinitis medicamentosa review. European Annals of Otorhinolaryngology, Head and Neck Diseases, 130(3), 137–144. https://doi.org/10.1016/j.anorl.2012.09.005
55. Aaronson, D. W. (1998). Side effects of rhinitis medications. Journal of Allergy and Clinical Immunology, 101(6), S379–S382.
56. Deckx, L., De Sutter, A. I., Guo, L., et al. (2016). Nasal decongestants for common cold. Cochrane Database of Systematic Reviews, CD009612.
57. Thomas, J., Pandhi, R. K., Oberoi, C., et al. (1998). Loratadine vs cetirizine in urticaria. Indian Journal of Dermatology, Venereology and Leprology, 64, 12–16.
58. Zuberbier, T., Münzberger, C., & Haustein, U. F. (1996). High-dose cetirizine in cholinergic urticaria. Dermatology, 193(4), 324–327. https://doi.org/10.1159/000246281
59. World Health Organization. (2006). Reproductive health indicators: Guidelines for their generation, interpretation and analysis for global monitoring. WHO.
60. Mehta, N., Chen, K., & Powrie, R. O. (2014). Prescribing for pregnant patients. Cleveland Clinic Journal of Medicine, 81(6), 367–372. https://doi.org/10.3949/ccjm.81a.13124
61. Gonzalez-Estrada, A., & Geraci, S. A. (2016). Allergy medications during pregnancy. American Journal of Medical Sciences, 352(4), 326–331. https://doi.org/10.1016/j.amjms.2016.05.030
62. Ban, G. Y., Kim, M. Y., Yoo, H. S., et al. (2014). Elderly chronic urticaria. Korean Journal of Internal Medicine, 29(6), 800–806. https://doi.org/10.3904/kjim.2014.29.6.800
63. Chuamanochan, M., Kulthanan, K., Tuchinda, P., et al. (2016). Chronic urticaria in aging population. Asia Pacific Journal of Allergy and Immunology, 34(3), 201–205. https://doi.org/10.12932/AP0708
64. Song, W. J., & Chang, Y. S. (2017). Respiratory allergies in the elderly. Asia Pacific Allergy, 7(4), 185–192. https://doi.org/10.5415/apallergy.2017.7.4.185
65. Divo, M. J., Martinez, C. H., & Mannino, D. M. (2014). Ageing and multimorbidity. European Respiratory Journal, 44(4), 1055–1068. https://doi.org/10.1183/09031936.00059814
66. Pinto, J. M., & Jeswani, S. (2010). Rhinitis in geriatric population. Allergy Asthma & Clinical Immunology, 6, 10. https://doi.org/10.1186/1710-1492-6-10
67. Slavin, R. G. (2009). Treating rhinitis in older adults. Allergy Asthma & Clinical Immunology, 5, 9. https://doi.org/10.1186/1710-1492-5-9
68. Bowden, T., & Coiera, E. (2017). Accessing primary care records. BMC Medical Informatics and Decision Making, 17, 138. https://doi.org/10.1186/s12911-017-0523-4
69. Nyenhuis, S. M., & Mathur, S. K. (2013). Rhinitis in older adults. Current Allergy and Asthma Reports, 13(2), 171–177. https://doi.org/10.1007/s11882-013-0342-3
70. Maeda, T., Babazono, A., & Nishi, T. (2018). First-generation antihistamine use in dementia patients. Current Gerontology and Geriatrics Research, 2018, 3406210. https://doi.org/10.1155/2018/3406210
71. Olasinska-Wisniewska, A., Olasinski, J., & Grajek, S. (2014). Cardiovascular safety of antihistamines. Postępy Dermatologii i Alergologii, 31(3), 182–186. https://doi.org/10.5114/pdia.2014.43191
72. Philpot, E. E. (2000). Safety of second-generation antihistamines. Allergy Asthma Proceedings, 21(1), 15–20. https://doi.org/10.2500/108854100778249033